International Conference on Transcriptomics July 27-29, 2015 Orlando, FL, USA

Jarrett received his Ph.D. from the Univ. North Carolina-Chapel Hill in 1976. After postdoctoral fellowships at the Mayo Clinic, UCSD, and U.GA , he began an assistant professorship at IN U-Purdue U at Indianapolis. After promotion he joined the faculty at the U. TN Health Science Center where he was promoted to professor and remained for 18 years. In 2006, he joined the faculty at U. TX San Antonio as the Lutcher Brown Distinguished Professor of Biochemistry where he remains. His research has involved the purification of transcription factors and the RNA pol 2 transcription complex. His discoveries have included coupling methods which led to the first DNA-silica HPLC columns and developed both oligonucleotide trapping and promoter trapping to purify transcription proteins for mass spectrometry characterization. Most recently, this research has involved coating MALDI plates to direct proteomic discovery to DNA-binding proteins for a new method called T3.

Genomics and Proteomics

Andrey S. Krasilnikov has received his PhD degree from the Institute of Chemical Physics (Moscow, Russia) in 1995. During his postdoctoral training at the UIC and Northwestern University (Chicago, USA) he became interested in enzymes that rely on their RNA moiety for catalysis. He is currently an Associate Professor of Biochemistry and Molecular Biology at the Penn State University. The main focus of his research is the structure and function of the multicomponent eukaryotic catalytic ribonucleoproteins of the RNase P/MRP family. He has authored more than 30 publications in the fields of biochemistry, molecular and structural biology, and physics.

biochemistry, molecular and structural biology

Alan J. Tackett has obtained his PhD from University of Arkansas for Medical Sciences in 2002. Currently, he is working as Associate Professor in University of Arkansas. He is serving as an editorial member of several reputed journals like Conference Papers in Biology. He has authored 41 research articles/books. In 2011 he received UAMS Founders Society Research Award.

His areas of expertise include proteomics, epigenetic technology development, and melanoma cancer biology. We currently pursue a series of proteomic studies including the most comprehensive to date proteomic analysis of FFPE patient melanoma. Additionally, he direct the UAMS Proteomics Facility and have extensive experience in collaborative research projects involving various areas of mass spectrometry. His group has expertise in using mass spectrometry to identify proteins in complex mixtures as well as quantifying protein abundance using various procedures (e.g., label-free, spectral counting, stable isotope tags & SILAC). They also perform various quantitative analyses of posttranslational modifications.

Wei Zhang is a Professor in Pathology and Cancer Biology in the Department of Pathology and the director of the Cancer Genomics Laboratory at MD Anderson Cancer Center. Dr. Zhang has published more than close to 300 peer-reviewed papers and 21 book chapters. Dr. Zhang co-edited two books (Statistical and Computational Approaches to Genomics, 1st and 2nd edition, and Genomic and Molecular Neuro-Oncology) and co-authored one book (Microarray Quality Control). Dr. Zhang is a co-director of one of seven Genome Data Analysis Centers (GDAC) under the Cancer Genome Atlas (TCGA) project funded by NCI

Cancer Genomics

Gitte L. Pedersen has more than 20 years of management experience in the biotech and pharma industry. She has held a number of executive positions at NovoZymes, where she successfully developed and launched new products worldwide. In 1997 she established an advisory firm, Proximity Ventures, and in that capacity, she has advised a number of biotech and government institutions resulting in numerous licensing and equity deals with companies such as GSK, JnJ, Merck, P&G, Wyeth, and Takeda. Her aggregated deal resume is more than $1 billion. Gitte Pedersen is the co-founder of Genomic Expression and has served as its CEO since 2009. Gitte has a masters in chemical engineering and a business degree.

Transcriptomics and Genomics

Momiao Xiong is a Professor at Division of Biostatistics and Human Genetics Center, School of Public Health, the University of Texas Health Science Center at Houston . He obtained his PhD degree from the Department of Statistics at the University of Georgia in 1993 and finished his postdoctoral training in computational biology from the University of Southern California in 1995.

His research is in the area of statistical genetics, bioinformatics, machine learning and image analysis.

Yosef Yarden completed his Ph.D from The Weizmann Institute of Science; Rehovot, Israel in the year 1985. Later he went for his postdocs and got appointed as a Senior Scientist in Department of Immunology in The Weizmann Institute in 1988. Currently he is working as a Professor in Department of Molecular Cell Biology in the same institute. He has many awards on his name mentioning some the EMET prize in Biochemistry in 2007 and the MERIT award of the U.S. National Cancer Institute in 2005.

Molecular Cell Biology, Immunology

Carolyn Compton is an academic pathologist who received her MD and PhD degrees from Harvard Medical School. At ASU, she is the Chief Medical and Science Officer of the National Biomarkers Development Alliance, a member of the Biodesign Institute and the Chief Medical Officer of the Complex Adaptive Systems Initiative. Her research interests are related to colon cancer, bio-banking and biomarkers development. She was a professor of pathology at Harvard and Massachusetts General Hospital, Chair of Pathology at McGill University from 2000-2005, and Director of the Office of Biorepositories and Biospecimen Research at the National Cancer Institute until 2012. She is the past CEO and President of the Critical Path Institute. Compton is an adjunct professor of pathology at both the University of Arizona and Johns Hopkins, and research associate at Mayo Clinic.

Biomedicine, Cancer, Diseases, Health, Pathology

Associate Professer at Weizmann Institute of Science

Molecular biology

Farid Menaa (Bsc. Eng., Bsc. Bio., Msc. Genetics, Master Gerontology/Geriatry, PhD Radiation Oncology and Gerontology, three international post-doctoral terms, EMBA Entrepreneurship and MD candidate), is an experienced and skilled inter- and multi-disciplinary professional. Professor, Principal Investigator, Executive Director, Consultant, Advisor, Editor, Reviewer, Event Organizer and Entrepreneur, Dr. Menaa earned his degrees with high distinctions from prestigious universities and institutions.

Menaa´s R&D interests include the integration of innovative green techniques, state-of-the art technologies, methods and applications for personalized and translational medicine, in particular to improve the outcomes of cancer patients, stroke patients, and infected individuals as well as to delay the aging process. In the pharmaceutical fied, Dr. Menaa is interested in the drugs and natural compounds characterization, the design and development of new formulations. Dr. Menaa co-pioneered the development of a disruptive, green, non-invasive and versatile technology called Spectro-Fluor™ for pharmaceutical and biomedical applications.

Punit Kaur finished her B.Sc. in 1999 with Botany, Zoology and Chemistry from Punjab University, Chandigarh, India. Then she went for Postgrad (M.Sc.) (1999-2001) in Microbiology from Guru Nanak Dev University, Amritsar, Punjab, India. Later she pursued for Ph.D (2001-2008) on the topic Experimental Medicine and Biotechnology from the Postgraduate Institute of Medical Education and Research, Chandigarh, India

Punit Kaur along with other members of the organization focus on the research and development of heat shock protein-based therapies to be used alone or in combination with current therapies for the eradication of triple-negative breast cancer. Recent studies on surface receptors and gene expression of breast tumors have come up with a term triple-negative breast cancer (TNBC), creating a phenotype and disease quite distinct from that seen in HER2- or ER-positive breast cancers, which is a much more aggressive disease without tumor-specific treatment options. Our studies employ gold nanoshell-mediated hyperthermia in combination with radiotherapy and chemotherapy, also known as the triple-modality approach. These studies received RGP Award from Scott & White Memorial Hospital.

Subha Bhassu completed her graduation BSc. (Biomedical Sciences) in the year 1996 from University Kebangsaan Malaysia, Kualalumpur. Later she did her PhD in Molecular Biology from University Putra Malaysia. In the year 2010 she got appointed as CEBAR Biosafety Commitee(CBC) Member.

Population Genetics (Genomics, Quantitative Genetics and Evolutionary Biology). Inland Fisheries (Ecological Genetics and Morphometric and Conservation genetics). Genomic(Genome Informatics for Eukaryotic System)